PROLONGED SURVIVAL OF A PATIENT WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B AND STAGE IV MEDULLARY THYROID CARCINOMA

2003 ◽  
Vol 9 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Géza Mózes, MD, PhD ◽  
Jon A. van Heerden, MD ◽  
Hossein Gharib, MD, FACE
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Stage Iv ◽  
Prolonged Survival ◽  
Medullary Thyroid ◽  
Endocrine Neoplasia ◽  
Endocrine Neoplasia Type

scholarly journals Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B

2018 ◽  
Vol 88 (5) ◽  
pp. 754-756 ◽  
Author(s):  
Nicholas Thomas ◽  
John Glod ◽  
Claudia Derse-Anthony ◽  
Emma L. Baple ◽  
Nigel Osborne ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Medullary Thyroid ◽  
Endocrine Neoplasia ◽  
Endocrine Neoplasia Type

scholarly journals Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary

2001 ◽  
Vol 170 (3) ◽  
pp. 661-666 ◽  
Author(s):  
I Klein ◽  
O Esik ◽  
V Homolya ◽  
F Szeri ◽  
A Varadi
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Medullary Thyroid ◽  
Familial Medullary Thyroid Carcinoma ◽  
Clinical Criteria ◽  
Ret Protooncogene ◽  
Endocrine Neoplasia ◽  
Endocrine Neoplasia Type

Medullary thyroid carcinoma (MTC) occurs usually in sporadic form, but about a quarter of the cases are hereditary and appear as part of one of the multiple endocrine neoplasia type 2 (MEN2) syndromes. Mutations in the RET protooncogene are known to be the cause of the MEN2A and familial medullary thyroid carcinoma (FMTC) syndromes in the majority of the families. Direct DNA testing allows prophylactic thyroidectomy to be offered to individuals carrying a mutation in the above codons, and in mutation-negative cases it reduces the yearly screening-related burden on family members at risk of the disease. By DNA sequencing and PCR-restriction fragment length polymorphisms, 65 MTC probands were examined for mutations in residues 609, 611, 618, 620 of exon 10, and in residues 634, 768, 804 of exons 11, 13, and 14 respectively of the RET protooncogene. In our study, mutations in the above codons were detected in all of the 14 clinically MEN2A and FMTC families. One of these mutations, TGC609 TCC has not been reported previously. Of the 14 probands with the mutation, 25 relatives also had the identified mutation and 18 relatives proved to be non-carriers. Among the 51 probands with clinically sporadic MTC, none was found to carry a mutation in the above positions even if indirect signs of MTC, pheochromocytoma or hyperparathyroidism could be detected in some families. The frequency of the TGC634AGC mutation is unexpectedly high in our samples, which can probably be attributed to a founder effect. We conclude that screening for mutations in these codons is effective in families fulfilling the strict clinical criteria of MEN2A or FMTC.

Sign in / Sign up

Export Citation Format

Share Document